Developer docs
API playgroundTry for free, no card

Search company profiles

Neumirna Therapeutics

Full company profile

uuid0000e59

Namestring
Neumirna Therapeutics
Legal namestring
Neumirna Therapeutics ApS
Websiteurl
neumirna.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Neumirna Therapeutics ApS is a Copenhagen-based, clinical-stage biotechnology company developing miRNA-targeting antisense oligonucleotide (ASO-LNA) therapies for neurological diseases. The company's proprietary platform uses chemically modified ASOs with locked nucleic acid (LNA) chemistry to inhibit overactive microRNAs, aiming to rebalance disease-relevant brain networks rather than merely suppress symptoms. Its lead candidate NMT.001 targets miR-134 for drug-resistant epilepsy and is positioned for Phase 1/2a clinical trials (MiRNova study) starting in early 2027. The pipeline includes NMT.002 (miR-27b targeting ASO for Parkinson's disease, preclinical), plus two undisclosed candidates (NMT.003 and NMT.004) in screening, supported by a 24-36 month target-identification-to-clinic development cadence.

The company was founded in 2020 by Dr. Henrik Klitgaard (discoverer of the SV2A mechanism underlying UCB's Keppra and Brivaracetam), Prof. Sakari Kauppinen (discoverer of Miravirsen, the world's first miRNA-targeted drug at Santaris Pharma), and serial biotech entrepreneur Lars Hellerung Christiansen. Neumirna operates from Copenhagen, Basel, and Boston with 1-10 employees, and is led by CEO Ellen K. Donnelly (ex-Abliva AB, Pfizer neuroscience), CDO Ina Brünig-Traebert (ex-Roche RNA therapy program for Angelman Syndrome), and CMO Dr. Ferenc Tracik (ex-NeuroSense, Biogen, Novartis). The Scientific Advisory Board includes Prof. Jacqueline French (NYU Langone) and Prof. Karl Kieburtz (University of Rochester).

Neumirna is pre-revenue and monetizes through future product commercialization or licensing rather than current sales. Capital is sourced from a €20M Series A (January 2025, co-led by Angelini Ventures and Invivo Partners) plus non-dilutive grants from The Michael J. Fox Foundation ($650K), CURE Epilepsy ($250K), the Epilepsy Foundation ($200K), and Innovation Fund Denmark (5M DKK Innobooster). Customers are future-facing: target patient populations include the ~50 million people worldwide with epilepsy, of whom approximately one-third are treatment-resistant, as well as Parkinson's disease patients. Go-to-market relies on scientific conferences (AES, AD/PD), investor/partnering events (BIO Europe, BioEquity, Jefferies, NLS Days), patient advocacy engagement, and academic collaborations with institutions including Aalborg University, RCSI, DTU, University of Copenhagen, and Vall d'Hebron University Hospital.

Short descriptiontext

Neumirna Therapeutics is a Copenhagen-based clinical-stage biotechnology company developing miRNA-targeting antisense oligonucleotide (ASO-LNA) therapies for neurological diseases, with lead candidate NMT.001 advancing toward Phase 1/2a trials in drug-resistant epilepsy in 2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA therapeutics, antisense oligonucleotides, neurological disease treatments, microRNA targeting, epilepsy drug development
Industry4 codes
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Neurology RNA Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1RNA Therapeutics Development
TypeOne Time License
Description

Pre-revenue biotech company developing RNA-based therapeutics for neurological diseases. Revenue generation will come from future product sales following regulatory approval.

neumirna.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Neumirna Therapeutics develops miRNA-targeting antisense oligonucleotide (ASO-LNA) therapies for neurological diseases, with a lead candidate NMT.001 in clinical development for drug-resistant epilepsy. The company operates a proprietary drug discovery platform spanning target identification, ASO design, in vitro screening, lead optimization, and IND-enabling studies, designed to advance candidates from idea to clinic within 24-36 months. Its pipeline includes NMT.001 (miR-134, epilepsy, Phase 1/2a), NMT.002 (miR-27b, Parkinson's, preclinical), and two undisclosed preclinical programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • NMT.001 demonstrated adequate safety margins across relevant preclinical studies, supporting continued progress toward the clinic
+2 more records
Product overview1 text field

Neumirna Therapeutics is a biotech company developing a portfolio of miRNA-targeting antisense oligonucleotide (ASO-LNA) therapies for neurological diseases. The company's core offering consists of a proprietary ASO-LNA platform and multiple pipeline candidates: NMT.001 (lead candidate targeting miR-134 for drug-resistant epilepsy, in Phase 1/2a), NMT.002 (targeting miR-27b for Parkinson's disease, preclinical), and two undisclosed programs (NMT.003 and NMT.004). The platform enables targeted intrathecal delivery of RNA therapeutics designed to slow or reverse disease progression by modulating microRNAs—master regulators of gene expression in neurological disorders.

Product and service5 records
1NMT.001
CategoryClinical-stage therapeutic candidate
Description

First-in-class antisense oligonucleotide (ASO-LNA) therapy targeting microRNA-134 (miR-134) for the treatment of drug-resistant epilepsy. Designed for intrathecal delivery to the central nervous system with potential for twice-yearly administration and disease-modifying effects, intended for patients whose seizures are not controlled by existing anti-seizure medications.

2NMT.002
CategoryPreclinical therapeutic candidate
Description

ASO-LNA compound targeting microRNA-27b (miR-27b) for the treatment of Parkinson's disease. Currently in preclinical development, with the program aiming to deliver a disease-modifying RNA therapy for progressive movement disorders in collaboration with Motac Neuroscience and the Center for RNA Medicine at Aalborg University.

3NMT.003
CategoryDiscovery-stage therapeutic candidate
Description

ASO-LNA compound with undisclosed target for an undisclosed neurological indication. Currently in the screening stage of development as part of Neumirna's multi-asset pipeline.

4NMT.004
CategoryDiscovery-stage therapeutic candidate
Description

ASO-LNA compound with undisclosed target for an undisclosed neurological indication. Currently in the screening stage of development as part of Neumirna's multi-asset pipeline.

5ASO-LNA Development Platform
CategoryRNA therapeutics discovery platform
Description

Proprietary drug discovery and development platform that combines antisense oligonucleotide (ASO) chemistry with locked nucleic acid (LNA) modifications for targeted intrathecal delivery of RNA-based therapeutics. Spans target identification, ASO design, in vitro screening, lead optimization, in vivo proof of concept, and CMC/toxicology, with the goal of moving from idea to clinical testing within 24-36 months.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-01
Description

Collaborating on MJFF-funded project for disease-modifying RNA therapies for Parkinson's disease, bringing expertise in preclinical models for neurodegenerative diseases.

2Center for RNA Medicine at Aalborg University
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-01
Description

Academic partner in Parkinson's disease research collaboration, contributing research excellence in RNA medicine.

neumirna.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaborator on drug discovery pipeline for Parkinson's disease RNA therapies. Home of Center for RNA Medicine.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic collaborator listed on company website.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic collaborator listed on company website.

6University of Copenhagen
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic collaborator listed on company website.

neumirna.com
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical collaborator with Dr. Manuel Toledo from Scientific Advisory Board.

8Epilepsy Study Consortium
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Collaborator founded by Scientific Advisory Board member Dr. Jacqueline French, helps define how early-stage epilepsy trials are conducted.

neumirna.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large biotech with deep CNS franchise, including Spinraza (ASO for SMA). Comparable in CNS therapeutic focus and serves as a likely M&A or commercialization partner for late-stage CNS ASOs.

TypeDirect peer
Description

Clinical-stage company developing stereopure antisense oligonucleotides for neurological diseases (e.g., Huntington's, ALS). Directly comparable platform technology and CNS disease focus.

TypeBroad incumbent
Description

Commercial-stage leader in RNA interference therapeutics (siRNA), including Onpattro and Givlaari. Adjacent RNA-based therapeutic modality targeting CNS/neurological indications.

TypeEmerging player
Description

Emerging player developing small-molecule RNA splicing modulators for neurological diseases. Comparable in CNS therapeutic focus and RNA-targeting approach but uses different chemistry.

TypeEmerging player
Description

Emerging biotech developing RNAi therapeutics for neurological diseases including Huntington's. Comparable in CNS RNA-targeted approach and disease-modifying positioning.

TypeBroad incumbent
Description

Pharma incumbent with significant ASO/CNS pipeline including tofersen (with Ionis) for SOD1 ALS and former development of Rugonersen (now Roche-led). Key competitor and potential partner for Neumirna's ASO-LNA programs.

TypeEmerging player
Description

Clinical-stage biotech focused on neurodegeneration with multiple modalities. Comparable in CNS therapeutic area focus and disease-modifying positioning, though broader modality mix.

TypeBroad incumbent
Description

Established leader in antisense oligonucleotide drug development with a broad CNS pipeline including Spinraza (marketed) and tofersen. Sets the competitive baseline for ASO technology, manufacturing, and CNS clinical development.

TypeEmerging player
Description

Clinical-stage RNA editing / oligonucleotide company with CNS programs. Comparable in modality (RNA-based) and therapeutic area (neurological/genetic diseases).

TypeDirect peer
Description

Clinical-stage biotech developing antisense oligonucleotide therapies for neurological diseases (e.g., STK-001 for Dravet syndrome). Closest direct peer to Neumirna, also pursuing disease-modifying CNS ASOs with intrathecal delivery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neumirna Therapeutics

Neurology RNA Therapeuticsneumirna.com

Neumirna Therapeutics is a Copenhagen-based clinical-stage biotechnology company developing miRNA-targeting antisense oligonucleotide (ASO-LNA) therapies for neurological diseases, with lead candidate NMT.001 advancing toward Phase 1/2a trials in drug-resistant epilepsy in 2027.

What Neumirna Therapeutics does

Neumirna Therapeutics ApS is a Copenhagen-based, clinical-stage biotechnology company developing miRNA-targeting antisense oligonucleotide (ASO-LNA) therapies for neurological diseases. The company's proprietary platform uses chemically modified ASOs with locked nucleic acid (LNA) chemistry to inhibit overactive microRNAs, aiming to rebalance disease-relevant brain networks rather than merely suppress symptoms. Its lead candidate NMT.001 targets miR-134 for drug-resistant epilepsy and is positioned for Phase 1/2a clinical trials (MiRNova study) starting in early 2027. The pipeline includes NMT.002 (miR-27b targeting ASO for Parkinson's disease, preclinical), plus two undisclosed candidates (NMT.003 and NMT.004) in screening, supported by a 24-36 month target-identification-to-clinic development cadence.

The company was founded in 2020 by Dr. Henrik Klitgaard (discoverer of the SV2A mechanism underlying UCB's Keppra and Brivaracetam), Prof. Sakari Kauppinen (discoverer of Miravirsen, the world's first miRNA-targeted drug at Santaris Pharma), and serial biotech entrepreneur Lars Hellerung Christiansen. Neumirna operates from Copenhagen, Basel, and Boston with 1-10 employees, and is led by CEO Ellen K. Donnelly (ex-Abliva AB, Pfizer neuroscience), CDO Ina Brünig-Traebert (ex-Roche RNA therapy program for Angelman Syndrome), and CMO Dr. Ferenc Tracik (ex-NeuroSense, Biogen, Novartis). The Scientific Advisory Board includes Prof. Jacqueline French (NYU Langone) and Prof. Karl Kieburtz (University of Rochester).

Neumirna is pre-revenue and monetizes through future product commercialization or licensing rather than current sales. Capital is sourced from a €20M Series A (January 2025, co-led by Angelini Ventures and Invivo Partners) plus non-dilutive grants from The Michael J. Fox Foundation ($650K), CURE Epilepsy ($250K), the Epilepsy Foundation ($200K), and Innovation Fund Denmark (5M DKK Innobooster). Customers are future-facing: target patient populations include the ~50 million people worldwide with epilepsy, of whom approximately one-third are treatment-resistant, as well as Parkinson's disease patients. Go-to-market relies on scientific conferences (AES, AD/PD), investor/partnering events (BIO Europe, BioEquity, Jefferies, NLS Days), patient advocacy engagement, and academic collaborations with institutions including Aalborg University, RCSI, DTU, University of Copenhagen, and Vall d'Hebron University Hospital.

Neumirna Therapeutics firmographics

Firmographics
Name
Neumirna Therapeutics
Legal name
Neumirna Therapeutics ApS
Website
https://neumirna.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Neumirna Therapeutics is a Copenhagen-based clinical-stage biotechnology company developing miRNA-targeting antisense oligonucleotide (ASO-LNA) therapies for neurological diseases, with lead candidate NMT.001 advancing toward Phase 1/2a trials in drug-resistant epilepsy in 2027.
Ownership category
akta.pro rank

Neumirna Therapeutics industry classification

Industry
Product category
Neurology RNA Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • RNA therapeutics
  • Antisense oligonucleotides
  • Neurological disease treatments
  • MicroRNA targeting
  • Epilepsy drug development

Where Neumirna Therapeutics is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices3 records

Markets served

Neumirna Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. RNA Therapeutics Development: Pre-revenue biotech company developing RNA-based therapeutics for neurological diseases. Revenue generation will come from future product sales following regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Neumirna Therapeutics product offering

Product offering

Core offering

Neumirna Therapeutics develops miRNA-targeting antisense oligonucleotide (ASO-LNA) therapies for neurological diseases, with a lead candidate NMT.001 in clinical development for drug-resistant epilepsy. The company operates a proprietary drug discovery platform spanning target identification, ASO design, in vitro screening, lead optimization, and IND-enabling studies, designed to advance candidates from idea to clinic within 24-36 months. Its pipeline includes NMT.001 (miR-134, epilepsy, Phase 1/2a), NMT.002 (miR-27b, Parkinson's, preclinical), and two undisclosed preclinical programs.

Product overview

Neumirna Therapeutics is a biotech company developing a portfolio of miRNA-targeting antisense oligonucleotide (ASO-LNA) therapies for neurological diseases. The company's core offering consists of a proprietary ASO-LNA platform and multiple pipeline candidates: NMT.001 (lead candidate targeting miR-134 for drug-resistant epilepsy, in Phase 1/2a), NMT.002 (targeting miR-27b for Parkinson's disease, preclinical), and two undisclosed programs (NMT.003 and NMT.004). The platform enables targeted intrathecal delivery of RNA therapeutics designed to slow or reverse disease progression by modulating microRNAs—master regulators of gene expression in neurological disorders.

Differentiator

Problem solved

Functional benefit

Products and services

  • NMT.001 First-in-class antisense oligonucleotide (ASO-LNA) therapy targeting microRNA-134 (miR-134) for the treatment of drug-resistant epilepsy. Designed for intrathecal delivery to the central nervous system with potential for twice-yearly administration and disease-modifying effects, intended for patients whose seizures are not controlled by existing anti-seizure medications.
  • NMT.002 ASO-LNA compound targeting microRNA-27b (miR-27b) for the treatment of Parkinson's disease. Currently in preclinical development, with the program aiming to deliver a disease-modifying RNA therapy for progressive movement disorders in collaboration with Motac Neuroscience and the Center for RNA Medicine at Aalborg University.
  • NMT.003 ASO-LNA compound with undisclosed target for an undisclosed neurological indication. Currently in the screening stage of development as part of Neumirna's multi-asset pipeline.
  • NMT.004 ASO-LNA compound with undisclosed target for an undisclosed neurological indication. Currently in the screening stage of development as part of Neumirna's multi-asset pipeline.
  • ASO-LNA Development Platform Proprietary drug discovery and development platform that combines antisense oligonucleotide (ASO) chemistry with locked nucleic acid (LNA) modifications for targeted intrathecal delivery of RNA-based therapeutics. Spans target identification, ASO design, in vitro screening, lead optimization, in vivo proof of concept, and CMC/toxicology, with the goal of moving from idea to clinical testing within 24-36 months.

Quantifiable outcome

  • NMT.001 demonstrated adequate safety margins across relevant preclinical studies, supporting continued progress toward the clinic
  • +2 more outcomes

Companies that use Neumirna Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Neumirna Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Neumirna Therapeutics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and supporting.

  • Motac NeurosciencecoreStrategic or Co-development Partner · 1 August 2023Collaborating on MJFF-funded project for disease-modifying RNA therapies for Parkinson's disease, bringing expertise in preclinical models for neurodegenerative diseases.
  • Center for RNA Medicine at Aalborg UniversitycoreStrategic or Co-development Partner · 1 August 2023Academic partner in Parkinson's disease research collaboration, contributing research excellence in RNA medicine.
  • Aalborg UniversitycoreStrategic or Co-development PartnerAcademic collaborator on drug discovery pipeline for Parkinson's disease RNA therapies. Home of Center for RNA Medicine.
  • Royal College of Surgeons Ireland (RCSI)supportingStrategic or Co-development PartnerAcademic collaborator listed on company website.
  • DTU (Technical University of Denmark)supportingStrategic or Co-development PartnerAcademic collaborator listed on company website.
  • University of CopenhagensupportingStrategic or Co-development PartnerAcademic collaborator listed on company website.
  • Vall d'Hebron University HospitalsupportingStrategic or Co-development PartnerClinical collaborator with Dr. Manuel Toledo from Scientific Advisory Board.
  • Epilepsy Study ConsortiumsupportingStrategic or Co-development PartnerCollaborator founded by Scientific Advisory Board member Dr. Jacqueline French, helps define how early-stage epilepsy trials are conducted.

Scale indicators7 records

Recent moves7 records

Expansion highlights7 records

Neumirna Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Biogen: Large biotech with deep CNS franchise, including Spinraza (ASO for SMA). Comparable in CNS therapeutic focus and serves as a likely M&A or commercialization partner for late-stage CNS ASOs.
  • Alnylam Pharmaceuticals: Commercial-stage leader in RNA interference therapeutics (siRNA), including Onpattro and Givlaari. Adjacent RNA-based therapeutic modality targeting CNS/neurological indications.
  • Roche / Genentech: Pharma incumbent with significant ASO/CNS pipeline including tofersen (with Ionis) for SOD1 ALS and former development of Rugonersen (now Roche-led). Key competitor and potential partner for Neumirna's ASO-LNA programs.
  • Ionis Pharmaceuticals: Established leader in antisense oligonucleotide drug development with a broad CNS pipeline including Spinraza (marketed) and tofersen. Sets the competitive baseline for ASO technology, manufacturing, and CNS clinical development.

Direct peers

  • Wave Life Sciences: Clinical-stage company developing stereopure antisense oligonucleotides for neurological diseases (e.g., Huntington's, ALS). Directly comparable platform technology and CNS disease focus.
  • Stoke Therapeutics: Clinical-stage biotech developing antisense oligonucleotide therapies for neurological diseases (e.g., STK-001 for Dravet syndrome). Closest direct peer to Neumirna, also pursuing disease-modifying CNS ASOs with intrathecal delivery.

Emerging players

  • Skyhawk Therapeutics: Emerging player developing small-molecule RNA splicing modulators for neurological diseases. Comparable in CNS therapeutic focus and RNA-targeting approach but uses different chemistry.
  • Atalanta Therapeutics: Emerging biotech developing RNAi therapeutics for neurological diseases including Huntington's. Comparable in CNS RNA-targeted approach and disease-modifying positioning.
  • Denali Therapeutics: Clinical-stage biotech focused on neurodegeneration with multiple modalities. Comparable in CNS therapeutic area focus and disease-modifying positioning, though broader modality mix.
  • ProQR Therapeutics: Clinical-stage RNA editing / oligonucleotide company with CNS programs. Comparable in modality (RNA-based) and therapeutic area (neurological/genetic diseases).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Neumirna Therapeutics social profiles

Digital presence

Neumirna Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neumirna Therapeutics leadership team

Management profile

Number of profiles

Profiles17 records

Neumirna Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neumirna Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neumirna Therapeutics

What does Neumirna Therapeutics do?

Neumirna Therapeutics develops miRNA-targeting antisense oligonucleotide (ASO-LNA) therapies for neurological diseases, with a lead candidate NMT.001 in clinical development for drug-resistant epilepsy. The company operates a proprietary drug discovery platform spanning target identification, ASO design, in vitro screening, lead optimization, and IND-enabling studies, designed to advance candidates from idea to clinic within 24-36 months. Its pipeline includes NMT.001 (miR-134, epilepsy, Phase 1/2a), NMT.002 (miR-27b, Parkinson's, preclinical), and two undisclosed preclinical programs.

Is Neumirna Therapeutics a public or private company?

Neumirna Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Neumirna Therapeutics founded?

Neumirna Therapeutics was founded in 2020. It employs 11 to 50 people.

Where is Neumirna Therapeutics based?

Neumirna Therapeutics is headquartered in Copenhagen, Denmark, in the Europe region.

How does Neumirna Therapeutics make money?

One revenue line is on record: RNA Therapeutics Development.

Who are Neumirna Therapeutics's main competitors?

Broad incumbents on record are Biogen, Alnylam Pharmaceuticals, Roche / Genentech and Ionis Pharmaceuticals. Direct peers are Wave Life Sciences and Stoke Therapeutics. Emerging players are Skyhawk Therapeutics, Atalanta Therapeutics, Denali Therapeutics and ProQR Therapeutics.

Does Neumirna Therapeutics have an API?

No public API is recorded for Neumirna Therapeutics.

What industry is Neumirna Therapeutics in?

Neumirna Therapeutics's product category is Neurology RNA Therapeutics. Its primary akta.pro industry code is HLAAADAC, Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown), with a secondary code of HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Arcticstartup€20M Series A boosts Danish Neumirna’s efforts in developing RNA therapies for neurological diseasesCopenhagen-based Neumirna Therapeutics raised €20M in a Series A round co-led by Angelini Ventures and Invivo Partners. The funding will accelerate clinical trials for its lead candidate NMT.001, an antisense oligonucleotide for drug-resistant epilepsy, and support R&D and platform scaling.FinSMEsNeumirna Therapeutics Raises €20M in Series A FundingNeumirna Therapeutics raised €20M in Series A funding led by Angelini Ventures and Invivo Partners. The company will use the funds to advance its lead ASO therapy NMT.001 for drug-resistant epilepsy and expand its R&D platform.GlobeNewswireAngelini Ventures co-leads €20 million Series A financing in Neumirna Therapeutics to Develop Next-Generation RNA Therapeutics for Epilepsy and other Neurological DisordersAngelini Ventures co-led a €20 million Series A financing in Neumirna Therapeutics, with Invivo Partners and other investors. The funds will advance its lead ASO NMT.001 for drug-resistant epilepsy into clinical development and expand R&D capabilities.GlobeNewswireAngelini Ventures co-leads €20 million Series A financing in Neumirna Therapeutics to Develop Next-Generation RNA Therapeutics for Epilepsy and other Neurological DisordersAngelini Ventures co-led a €20 million Series A financing in Neumirna Therapeutics, with participation from Invivo Partners and Innovestor's Life Science Fund. The funds will advance its lead asset NMT.001, an antisense oligonucleotide for drug-resistant epilepsy, into clinical development and expand R&D capabilities.Empresas de Capital Riesgo en EspaInvivo Partners leads €20 million Series A round in Neumirna Therapeutics with Angelini VenturesNeumirna Therapeutics closed its first Series A round at €20M, co-led by Angelini Ventures and Invivo Partners. The funding will advance its lead candidate NMT.001, an antisense oligonucleotide for drug-resistant epilepsy, toward clinical trials. Both lead investors joined the board.